Please be informed that Onxeo SA will be admitted to trading and official listing on NASDAQ OMX Copenhagen. First day of trading is 1 August 2014.
The merger between Onxeo (previously BioAlliance Pharma SA) and Topotarget has been adopted at the companies’ shareholder meetings and approved by the relevant authorities. Topotarget is the dis-continuing company. Onxeo SA has its primary listing on Euronext Paris.
| ISIN: | FR0010095596 |
| Name: | Onxeo |
| Volume: | 31,482,333 shares (DKK 7,870,583.25) |
| Face value: | EUR 0.25 |
| Currency: | EUR |
| Trade currency: | DKK |
| Voting rights of listed capital: | Full |
| Financial year: | 1 January to 31 December |
| Unlisted capital: | EUR 0 |
| French Organization number: | 410 910 095 RCS |
| Segment: | MidCap |
| Average Daily Turnover: | Will be calculated by the French FSA |
| Short name | ONXEO |
| Orderbook ID: | 101775 |
| Market Segment / no | OMX CPH Equities / 14 |
| Tick Size /no | XCSE Equities, DKK / 7 |
| MIC Code | XCSE |
Industry Classification Benchmark (ICB)
| 4000 | Health Care |
| 4500 | Health Care |
For further information, please contact: Asta Jepsen, Surveillance, tel. +45 33 93 33 66